Moderna Stock News

Moderna, Inc. (NASDAQ:MRNA) insider Juan Andres sold 5,000 shares of Moderna stock in a transaction dated Friday, December 17th. The stock was sold at an average price of $275.68, for a total value of $1,378,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. […]

LONDON: British pharmaceutical giant AstraZeneca said Thursday that a third, or "booster", dose of its Covid-19 vaccine Vaxzevria "significantly" lifted antibody levels against the Omicron strain in a laboratory study. "Vaxzevria significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster," the company said in a statement citing the study. "The third dose booster vaccination neutralised the Omicron variant to levels that were broadly similar to those observed after the second dose against the Delta variant," it said. Levels of neutralising antibodies were also higher with the booster jab than with individuals who had previously been infected and recovered naturally from Covid-19. The study was conducted by investigators from the University of Oxford, which is the academic institution which helped AstraZeneca develop the vaccine last year. Moderna says full booster dose improves Omicron protection The study analysed blood samples taken from individuals infected with Covid-19; those vaccinated with two doses plus a booster; and those who had reported previous Covid infection. "It is very encouraging to see that current vaccines have the potential to protect against Omicron following a third dose booster," said University of Oxford professor John Bell, one of the study investigators. "These results support the use of third dose boosters as part of national vaccine strategies, especially to limit the spread of variants of concern, including Omicron." On Wednesday, the World Health Organization had warned that rich countries cannot use boosters to escape the Covid crisis, as they divert valuable jabs away from poorer nations -- and encourage the virus to spread and mutate.

Yesterday, the University announced that Hopkins affiliates who work or study at its U.S. campuses will be required to get a Pfizer-BioNTech or Moderna COVID-19 booster shot by Feb. 1 Affiliates will need to upload documentation of their booster shot in the University''s Vaccine Management System . In interviews with The News-Letter , students expressed support for the mandate, and shared concerns about rising cases associated with the omicron variant . Freshman Katherine Burdinger endorsed the new booster requirement in an email to The News-Letter. "It''s an extra precaution to keep everyone safe, which I think is what we have to continue to do as long as [COVID-19] is a danger," she wrote. University administrators noted in the broadcast that people are eligible for booster shots six months after receiving a second shot of the Moderna or Pfizer-BioNTech COVID-19 vaccine, or two months after a single dose of the Johnson & Johnson/Janssen vaccine. Affiliates who are not eligible for the booster on Feb. 1 will be required to receive their booster dose within two weeks of becoming eligible.

A game-changing new antiviral treatment could dent the biotech''s coronavirus vaccine sales.

Top 10 Themes For 2022: Part 1 In its comprehensive take of the top 10 themes for 2022, Deutsche Bank''s Luke Templeman asks if covid is the only theme that matters ? He correctly responds that "that is not the right question. In fact, covid is now not so much a theme as it is the backdrop against which most things are evolving in economics, finance, and corporates." So what themes matter in 2022? As part of Deutsche Bank''s look ahead analysis, Templeman, director of the bank''s thematic research group, addresses the big macro topics the risk of the global economy overheating given stimulus measures and the change in attitude of central banks towards employment goals. Then there is how tight labor markets may further boost inflation. A flow on is higher bond yields and the end of free money that has propped up markets since the financial crisis. As he notes, while "stock markets may not crash, they could witness the return of fundamental investing." It certainly would be welcomed even if it comes with the S&P several hundred/thousand point lower.

COPENHAGEN (Reuters) Getting a third dose of either Pfizer-BioNTechs or Modernas COVID-19 vaccine offers a significant increase in protection against the Omicron variant in elderly people, according to a Danish study published on Wednesday.

The former union minister said the time has also come now to allow the use of other approved vaccines like Pfizer''s and Moderna''s.

Recipients of the Moderna COVID-19 vaccine are more likely to report side effects than those given the Johnson & Johnson or Pfizer-BioNTech shots, a study published Wednesday by JAMA Network Open found.

A panel at Japan''s health ministry refused to approve the Alzheimer''s drug, saying more data are needed to judge its effectiveness.

Oxfam America has filed a complaint with securities regulators accusing Moderna of providing misleading statements and concealing material information about its dispute with the U.S. government over Covid-19 vaccine patents.

WASHINGTON D.C.: According to a new study, vaccines developed by Johnson & Johnson, China''s Sinopharm and Russia''s Sputnik V are not as effective against the new Omicron variant. The study also found that the decrease was less pronounced for vaccinated people previously infected with the virus. It also showed vaccines from Moderna, AstraZeneca and Pfizer-BioNTech were still effective against Omicron, but

Human Rights Watch identified eight companies in Africa that could manufacture mRNA vaccines, if Moderna and Pfizer hand over the technology.

SYDNEY: Singapore suspended quarantine-free travel and Australia renewed its vaccination push on Wednesday as surging cases of the Omicron coronavirus variant just days before Christmas forced authorities to impose new curbs and expedite booster shots. Governments globally have tightened social mobility restrictions and made urgent pleas for citizens to vaccinate as Omicron emerges as the dominant strain of the virus, upending reopening plans that many hoped would herald the start of a post-pandemic era in 2022. In Asia-Pacific, Singapore will freeze all new ticket sales for flights and buses under its programme for quarantine-free travel into the city-state from Dec. 23 to Jan. 20, the government said on Wednesday, citing risk from the fast-spreading Omicron. "Our border measures will help to buy us time to study and understand the Omicron variant, and to strengthen our defences, including enhancing our healthcare capacity, and getting more people vaccinated and boosted," Singapore''s health ministry said in a statement.

World shares had fallen earlier in the week after Omicron infections multiplied but strong corporate earnings and reports that Moderna''s vaccine provides protection gave investors hope.